Strong cash flow generation in cash medicine market
History of building successful shockwave business, etc.
Expected future cash flow growth
CureSpec is selling Nephrospec to hospitals and clinics, initially targeting Europe (leveraging its CE approval), followed by the USA (after receiving FDA approval and establishing reimbursement codes), which together represent nearly 1.7 million potential patients a year using Nephrospec.
A potential market of over $15 billion a year.
CureSpec is raising $10 million for clinical trials (Europe/USA), reimbursement code for the treatment, FDA submission, and preliminary sales and marketing.